Autolus Therapeutics PLC Sponsored ADR

AUTL Healthcare Biotechnology

In the quarter to June 2026, revenue grew 118.4%, EPS grew 16.7% and free cash flow grew 67.6%, each against the same quarter a year earlier.

1.63 0.11 −6.32%
Market cap
$463.1M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
3/9
Altman Z
−3.17
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
— 3 2 —

+8 more TTM periods

ROE
(133.00%) (120.42%) (94.98%) (60.56%)
ROA
(46.15%) (45.38%) (41.92%) (30.19%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(85.46%) (78.71%) (67.49%) (45.11%)
Average Days of Receivables
138.03 109.01 116.32 232.76
Free Cash Flow per Share
(0.87) (1.08) (1.22) (1.15)
Free Cash Flow
(232.73) (286.81) (323.77) (306.77)
Capital Expenditures
(7.12) (13.49) (40.20) (52.59)
Other line items
Cash ROIC
(65.43%) (84.42%) (59.17%) (48.36%)
Accounts Receivable Turnover
3.31 4.41 6.27 1.37
Accounts Payable Turnover
29.23 32.54 38.15 11.69
Inventory Turnover
3.45 4.30 5.16 0.00
Average Days of Payables
5.04 6.63 11.68 55.28
Days of Inventory on Hand
123.24 117.78 125.78 139.73
Tax Rate
0.00 0.00 0.01 0.02
Research and Development Expense of Revenue
95.95% 121.10% 156.11% 220.79%
Selling, General and Administrative Expense of Revenue
130.49% 153.62% 174.93% 255.04%
Share Based Compensation of Revenue
13.15% 16.34% 19.15% 33.70%
Interest Coverage
(5.92) (7.03) (7.38) 16.11
Operating CF/Net income
0.81 0.95 0.99 1.13
Depreciation/Fixed assets
0.17 0.17 0.15 0.14
Capex/Depreciation
(0.68) (1.32) (4.10) (5.68)
Revenue per Share
0.44 0.35 0.28 0.19
Operating CF per Share
(0.85) (1.03) (1.07) (0.96)
Capex per Share
(0.03) (0.05) (0.15) (0.20)
Capex to Sales
0.06 0.15 0.53 1.03

Fold the line items

Columns are period end dates · fundamentals updated 28 Sep 2026